Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | GBA1 | P04062 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dembrexine SCHEMBL9247816 | 1.00 | CYP2D6 (0.72) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| Dembrexine SCHEMBL10426104 | 0.98 | CYP3A4 (0.72) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| Dembrexine SCHEMBL9247402 | 0.98 | CYP3A4 (0.72) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL11846315 | 0.86 | PABPC1 (0.58) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL11593068 | 0.85 | CYP2D6 (0.53) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL11593069 | 0.85 | CYP2D6 (0.53) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL11593172 | 0.85 | CYP2D6 (0.60) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL11593175 | 0.85 | CYP2D6 (0.60) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| Hydrochloric Acid SCHEMBL10426211 | 0.85 | PABPC1 (0.57) | CYP2D6CYP1A2HIF1ALMNAGBA1 | |
| SCHEMBL9628474 | 0.84 | CYP2D6 (0.52) | CYP2D6CYP1A2HIF1ALMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| EP-1789061-A1 | COPD TREATMENT AND MEDICAMENT | Max Zeller Söhne AG (CH) | 2007-05-30 | — | — | EP | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006000119-A1 | COPD TREATMENT AND MEDICAMENT | MAX ZELLER SOEHNE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5455266-A | Including an expectorant e.g bromhexine, ambroxol, dembrexine, and microbiocide in fish food; synergistic | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1995-10-03 | — | — | US | claimed |
| EP-0587135-A1 | Enhanced chemotherapeutic compositions against microbial infections in fish contaning a benzylamine derivative and an antimicrobial substance | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1994-03-16 | — | — | EP | claimed |
| EP-0586738-A1 | Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1994-03-16 | — | — | EP | claimed |
| EP-0138020-B1 | ANTI-ADHESIVE PROPHYLACTICA AND MEDICINES CONTAINING A SECRETOLYTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Dr. Karl Thomae GmbH (DE) | 1992-06-03 | — | — | EP | claimed |
| US-4705803-A | Method of improving resorption of injected antibacterially active substances or combinations | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1987-11-10 | — | — | US | claimed |
| EP-0088943-B1 | COMPOSITION FOR THE RESORPTION OF INJECTED ANTIBACTERIAL SUBSTANCES AND MIXTURES CONTAINING A BENZYL AMINE DERIVATIVE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-08-13 | — | — | EP | claimed |
| EP-0138020-A2 | Anti-adhesive prophylactica and medicines containing a secretolytically active benzylamine derivative | Dr. Karl Thomae GmbH (DE) | 1985-04-24 | — | — | EP | claimed |
| EP-0088943-A2 | Composition for the resorption of injected antibacterial substances and mixtures containing a benzyl amine derivative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1983-09-21 | — | — | EP | claimed |
| US-4113777-A | ANTISECRETORY, ANTITUSSIVE, ANTIULCER | BOEHRINGER INGELHEIM GMBH (DE) | 1978-09-12 | — | — | US | claimed |
| US-20230038019-A1 | COMPOSITIONS AND METHODS TO TREAT GASTROINTESTINAL DISEASES AND DISORDERS | CEDARS-SINAI MEDICAL CENTER | 2023-02-09 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3941461-A1 | COMPOSITIONS AND METHODS TO TREAT GASTROINTESTINAL DISEASES AND DISORDERS | Cedars-Sinai Medical Center (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2020191076-A1 | COMPOSITIONS AND METHODS TO TREAT GASTROINTESTINAL DISEASES AND DISORDERS | CEDARS-SINAI MEDICAL CENTER (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009120182-A2 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ACTIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090163449-A1 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ADDITIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| EP-1789061-A1 | COPD TREATMENT AND MEDICAMENT | Max Zeller Söhne AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006000119-A1 | COPD TREATMENT AND MEDICAMENT | MAX ZELLER SOEHNE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5455266-A | Including an expectorant e.g bromhexine, ambroxol, dembrexine, and microbiocide in fish food; synergistic | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0587135-A1 | Enhanced chemotherapeutic compositions against microbial infections in fish contaning a benzylamine derivative and an antimicrobial substance | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586738-A1 | Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0138020-B1 | ANTI-ADHESIVE PROPHYLACTICA AND MEDICINES CONTAINING A SECRETOLYTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Dr. Karl Thomae GmbH (DE) | 1992-06-03 | — | — | EP | disclosed |
| US-4918108-A | ADMINISTERING OXYTETRACYCLINE WITH DIBROMOBENZYLAMINE DERIVATIVE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1990-04-17 | — | — | US | disclosed |
| US-4705803-A | Method of improving resorption of injected antibacterially active substances or combinations | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0088943-B1 | COMPOSITION FOR THE RESORPTION OF INJECTED ANTIBACTERIAL SUBSTANCES AND MIXTURES CONTAINING A BENZYL AMINE DERIVATIVE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-08-13 | — | — | EP | disclosed |
| EP-0138020-A2 | Anti-adhesive prophylactica and medicines containing a secretolytically active benzylamine derivative | Dr. Karl Thomae GmbH (DE) | 1985-04-24 | — | — | EP | disclosed |
| EP-0088943-A2 | Composition for the resorption of injected antibacterial substances and mixtures containing a benzyl amine derivative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1983-09-21 | — | — | EP | disclosed |
| US-4113777-A | ANTISECRETORY, ANTITUSSIVE, ANTIULCER | BOEHRINGER INGELHEIM GMBH (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4073942-A | Halo-substituted hydroxybenzyl-amines as secretolytic agents | BOEHRINGER INGELHEIM GMBH (DT) | 1978-02-14 | — | — | US | disclosed |
| US-4073942-A | Halo-substituted hydroxybenzyl-amines as secretolytic agents | BOEHRINGER INGELHEIM GMBH (DT) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP2D6 4840/4885CYP1A2 4874/4885HIF1A 465/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CYP2D6 4709/4885CYP1A2 4806/4885HIF1A 180/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP2D6 4855/4885CYP1A2 4880/4885HIF1A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.